Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 28 of 28 publications.

Dave RH, Crayton H, Miravalle A, Tai MH, Wyse K, Houghton K, Hitchens A, Berkovich R. COVID-19 vaccination response in patients with multiple sclerosis treated with ofatumumab in the United States: a medical record review. Neurol Ther. 2024 Oct 23. doi: 10.1007/s40120-024-00671-0

Barrett A, Olayinka-Amao O, Ziemssen T, Bharadia T, Henke C, Kamudoni P. Understanding the symptoms and impacts experienced by people with relapsing-remitting MS: a qualitative investigation using semi-structured interviews. Neurol Ther. 2024 Apr;13(2):449-64. doi: 10.1007/s40120-024-00584-y

Callahan LF, Samsell B, DiBenedetti D, Frangiosa T, Slota C, Biggar V, Paulsen R, Lappin D, Herring WL, Romano (DeMuro) C. Evaluating elements of the care partner experience in individuals who care for people with Alzheimer's disease across the severity spectrum. Neurol Ther. 2024 Feb;13(1):53-67. doi: 10.1007/s40120-023-00558-6

Tahami Monfared AA, Phan NTN, Pearson I, Mauskopf J, Cho M, Zhang Q, Hampel H. A systematic review of clinical practice guidelines for Alzheimer's disease and strategies for future advancements. Neurol Ther. 2023 Aug;12(4):1257-84. doi: 10.1007/s40120-023-00504-6

Anderson-Smits C, Ritchey ME, Huang Z, Chavan S, Souayah N, Ay H, Layton BJ. Intravenous immunoglobulin treatment patterns and outcomes in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a US claims database analysis. Neurol Ther. 2023 Aug;12(4):1119-32. doi: 10.1007/s40120-023-00478-5

Layton JB, Ritchey ME, Huang Z, Chavan S, Ay H, Souayah N, Anderson-Smits C. Intravenous immunoglobulin initiation in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a US claims-based cohort study. Neurol Ther. 2023 Aug;12(4):1171-86. doi: 10.1007/s40120-023-00479-4

Hauber B, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Hartry A, Lee D, Wilson H, Hoffman DL, Weiberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Frangiosa T, Biggar V, Slota C, Romano (DeMuro) C, DiBenedetti D. Assessing what matters to people affected by Alzheimer's disease: a quantitative analysis. Neurol Ther. 2023 Apr;12(2):505-27. doi: 10.1007/s40120-023-00445-0

DiBenedetti D, Menne H, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Heithoff K, Hartry A, Oberdhan D, Wilson H, Hoffman DL, Weinberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Hauber B, Romano (DeMuro) C. Technical review of clinical outcomes assessments across the continuum of Alzheimer's disease. Neurol Ther. 2023 Apr;12(2):571-95. doi: 10.1007/s40120-023-00443-2

Forns J, Dudukina E, Hagg D, Szentkuti P, Gembert K, Plana E, Gilsenan A, Horvath-Puho E, Ehrenstein V, Reutfors J, Rebordosa C. Risk of major cardiovascular and cerebrovascular events in users of lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: a population-based cohort study. Neurol Ther. 2022 Dec 1;11(4):1659-76. doi: 10.1007/s40120-022-00396-y

Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025

Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Published Erratum - Correction to: Staging disease severity using the Alzheimer's Disease Composite Score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Jun;11(2):915-27. doi: 10.1007/s40120-022-00340-0

Zhang K, Karanth S, Patel B, Murphy R, Jiang X. A multi-task Gaussian process self-attention neural network for real-time prediction of the need for mechanical ventilators in COVID-19 patients. J Biomed Inform. 2022 Jun;130:104079. doi: 10.1016/j.jbi.2022.104079

Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Staging disease severity using the Alzheimer's disease composite score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Mar;11(1):413-34. doi: 10.1007/s40120-022-00326-y

Lewis S, Wray SE, Evans E, Romano (DeMuro) C, Bartolome L, Su W, Shah R, Russo PA. Patients' experiences in transitioning to secondary progressive multiple sclerosis: qualitative interviews. Neurol Ther. 2021 Dec;10(2):887-904. doi: 10.1007/s40120-021-00265-0

Herring WL, Gould IG, Fillit H, Lindgren P, Forrestal F, Thompson R, Pemberton-Ross P. Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer's disease. Neurol Ther. 2021 Dec;10(2):919-40. doi: 10.1007/s40120-021-00273-0

Mareque M, Montesinos P, Font P, Guinea JM, De La Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097

Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772

Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070

Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Barbe F, Castan MT, Seminario MA, Pujol J, Alseda M. Prevalence and characteristics of chronic obstructive pulmonary disease in non-smokers. Aten Primaria. 2019 Dec;51(10):602-9. doi: 10.1016/j.aprim.2017.10.012

Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Barbe F, Castan MT, Seminario MA, Pujol J, Alseda M. Comment: Prevalence and characteristics of chronic obstructive pulmonary disease in non-smokers. Aten Primaria. 2019 Nov;51(9):589-90.

Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913

Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609

Cruz-Esteve I, Marsal-Mora JR, Galindo-Ortego G, Galvan-Santiago L, Serrano-Godoy M, Ribes-Murillo E, Real-Gatius J, en representacion del grupo de investigacion GRETAP. Potentially inappropriate prescribing in older Spanish population according to STOPP/START criteria (STARTREC Study). Aten Primaria. 2017 Mar;49(3):166-76. doi: 10.1016/j.aprim.2016.02.013

Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.

Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe-Illa F. Risk factors for mortality in patients with chronic obstructive pulmonary disease. Aten Primaria. 2015 Oct;47(8):498-504. doi: 10.1016/j.aprim.2014.11.004

Dalley C, Basarir H, Wright JG, Fernando M, Pearson D, Ward SE, Thokula P, Krishnankutty A, Wilson G, Dalton A, Talley P, Barnett D, Hughes D, Porter NR, Reilly JT, Snowden JA. Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model. J Clin Pathol. 2015 Apr;68(4):292-300. doi: 10.1136/jclinpath-2014-202624

Puente D, Zabaleta-Del-Olmo E, Pueyo MJ, Salto E, Marsal JR, Bolibar B. Cigarette smoking prevalence and associated factors in secondary school children in Catalunya. Aten Primaria. 2013 Jun;45(6):315-23. doi: 10.1016/j.aprim.2012.12.007

Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.